These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1873 related articles for article (PubMed ID: 30902613)
1. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613 [TBL] [Abstract][Full Text] [Related]
2. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Nakagawa K; Hida T; Nokihara H; Morise M; Azuma K; Kim YH; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Kumagai T; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Koyama R; Mitsudomi T; Yamamoto N; Asakawa T; Hayashi M; Hasegawa W; Tamura T Lung Cancer; 2020 Jan; 139():195-199. PubMed ID: 31812890 [TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. Pérol M; Pavlakis N; Levchenko E; Platania M; Oliveira J; Novello S; Chiari R; Moran T; Mitry E; Nüesch E; Liu T; Balas B; Konopa K; Peters S Lung Cancer; 2019 Dec; 138():79-87. PubMed ID: 31654838 [TBL] [Abstract][Full Text] [Related]
4. Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer. Wolf J; Helland Å; Oh IJ; Migliorino MR; Dziadziuszko R; Wrona A; de Castro J; Mazieres J; Griesinger F; Chlistalla M; Cardona A; Ruf T; Trunzer K; Smoljanovic V; Novello S ESMO Open; 2022 Feb; 7(1):100333. PubMed ID: 35042152 [TBL] [Abstract][Full Text] [Related]
5. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Novello S; Mazières J; Oh IJ; de Castro J; Migliorino MR; Helland Å; Dziadziuszko R; Griesinger F; Kotb A; Zeaiter A; Cardona A; Balas B; Johannsdottir HK; Das-Gupta A; Wolf J Ann Oncol; 2018 Jun; 29(6):1409-1416. PubMed ID: 29668860 [TBL] [Abstract][Full Text] [Related]
6. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Gadgeel S; Peters S; Mok T; Shaw AT; Kim DW; Ou SI; Pérol M; Wrona A; Novello S; Rosell R; Zeaiter A; Liu T; Nüesch E; Balas B; Camidge DR Ann Oncol; 2018 Nov; 29(11):2214-2222. PubMed ID: 30215676 [TBL] [Abstract][Full Text] [Related]
7. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Mok T; Camidge DR; Gadgeel SM; Rosell R; Dziadziuszko R; Kim DW; Pérol M; Ou SI; Ahn JS; Shaw AT; Bordogna W; Smoljanović V; Hilton M; Ruf T; Noé J; Peters S Ann Oncol; 2020 Aug; 31(8):1056-1064. PubMed ID: 32418886 [TBL] [Abstract][Full Text] [Related]
8. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405). Isozaki H; Hotta K; Ichihara E; Takigawa N; Ohashi K; Kubo T; Ninomiya T; Ninomiya K; Oda N; Yoshioka H; Ichikawa H; Inoue M; Takata I; Shibayama T; Kuyama S; Sugimoto K; Harada D; Harita S; Sendo T; Tanimoto M; Kiura K Clin Lung Cancer; 2016 Nov; 17(6):602-605. PubMed ID: 27405684 [TBL] [Abstract][Full Text] [Related]
9. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer. Woo CG; Seo S; Kim SW; Jang SJ; Park KS; Song JY; Lee B; Richards MW; Bayliss R; Lee DH; Choi J Ann Oncol; 2017 Apr; 28(4):791-797. PubMed ID: 28039177 [TBL] [Abstract][Full Text] [Related]
10. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T; N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279 [TBL] [Abstract][Full Text] [Related]
11. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed. Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908 [TBL] [Abstract][Full Text] [Related]
12. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants. Li Y; Zhang T; Zhang J; Li W; Yuan P; Xing P; Zhang Z; Chuai S; Li J; Ying J Lung Cancer; 2018 Apr; 118():128-133. PubMed ID: 29571990 [TBL] [Abstract][Full Text] [Related]
13. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140 [TBL] [Abstract][Full Text] [Related]
14. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Zhou C; Kim SW; Reungwetwattana T; Zhou J; Zhang Y; He J; Yang JJ; Cheng Y; Lee SH; Bu L; Xu T; Yang L; Wang C; Liu T; Morcos PN; Lu Y; Zhang L Lancet Respir Med; 2019 May; 7(5):437-446. PubMed ID: 30981696 [TBL] [Abstract][Full Text] [Related]
15. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study. Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387 [TBL] [Abstract][Full Text] [Related]
16. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review. Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785 [TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer. Reckamp K; Lin HM; Huang J; Proskorovsky I; Reichmann W; Krotneva S; Kerstein D; Huang H; Lee J Curr Med Res Opin; 2019 Apr; 35(4):569-576. PubMed ID: 30286627 [TBL] [Abstract][Full Text] [Related]
18. Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India. Patel A; Batra U; Prasad KT; Dabkara D; Ghosh J; Sharma M; Singh N; Suresh P; Jain P; Malik PS; Choudhary P; Ganguly S; Khurana S; Ms S; Bothra S; Muthu V; Biswas B Curr Probl Cancer; 2020 Jun; 44(3):100571. PubMed ID: 32234264 [TBL] [Abstract][Full Text] [Related]
19. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Nishio M; Nakagawa K; Mitsudomi T; Yamamoto N; Tanaka T; Kuriki H; Zeaiter A; Tamura T Lung Cancer; 2018 Jul; 121():37-40. PubMed ID: 29858024 [TBL] [Abstract][Full Text] [Related]
20. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer. Gadgeel SM Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]